var data={"title":"Contrast-enhanced ultrasound for the evaluation of liver lesions","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Contrast-enhanced ultrasound for the evaluation of liver lesions</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/contributors\" class=\"contributor contributor_credentials\">Christoph F Dietrich, MD, MBA</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/contributors\" class=\"contributor contributor_credentials\">Jonathan B Kruskal, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/contributors\" class=\"contributor contributor_credentials\">Kristen M Robson, MD, MBA, FACG</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Oct 02, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H92235595\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Contrast-enhanced ultrasound (CEUS) is a diagnostic technique for imaging the liver and other organs [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/1-7\" class=\"abstract_t\">1-7</a>]. It is used in most of Europe and Asia, as well as in many other countries worldwide. The contrast agent, Lumason (<a href=\"topic.htm?path=sulfur-hexafluoride-lipid-microspheres-drug-information\" class=\"drug drug_general\">sulfur hexafluoride lipid microspheres</a>) was approved in 2016 by the Food and Drug Administration for the examination of the liver in adults and pediatric patients. </p><p>Guidelines for the use of ultrasound and CEUS-guided applications of the liver have been published [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/7-13\" class=\"abstract_t\">7-13</a>]. </p><p>This topic will review the role of CEUS in evaluating liver lesions, including the indications for the procedure and findings associated with various lesions. The general evaluation of liver lesions is discussed in detail elsewhere. (See <a href=\"topic.htm?path=solid-liver-lesions-differential-diagnosis-and-evaluation\" class=\"medical medical_review\">&quot;Solid liver lesions: Differential diagnosis and evaluation&quot;</a> and <a href=\"topic.htm?path=diagnosis-and-management-of-cystic-lesions-of-the-liver\" class=\"medical medical_review\">&quot;Diagnosis and management of cystic lesions of the liver&quot;</a>.) </p><p class=\"headingAnchor\" id=\"H92235607\"><span class=\"h1\">GENERAL PRINCIPLES</span></p><p class=\"headingAnchor\" id=\"H60347672\"><span class=\"h2\">Standard CEUS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Contrast-enhanced ultrasound (CEUS) uses ultrasound contrast agents to improve visualization and characterization of anatomic structures and lesions. It is most often performed transcutaneously, though it can also be used intraoperatively. There are several contrast agents available for CEUS. Ultrasound contrast agents are microbubbles consisting of gas bubbles stabilized by a shell. The most commonly used include sulfur hexafluoride with a phospholipid shell <span class=\"nowrap\">(SonoVue/Lumason),</span> octafluoropropane (perflutren with a lipid shell; <span class=\"nowrap\">Definity/Luminity),</span> and perfluorobutane with a phospholipid shell (Sonazoid). The contrast agent Lumason (<a href=\"topic.htm?path=sulfur-hexafluoride-lipid-microspheres-drug-information\" class=\"drug drug_general\">sulfur hexafluoride lipid microspheres</a>) was approved in 2016 by the Food and Drug Administration for the examination of the liver in adult and pediatric patients. (See <a href=\"topic.htm?path=contrast-echocardiography-contrast-agents-safety-and-imaging-technique#H6\" class=\"medical medical_review\">&quot;Contrast echocardiography: Contrast agents, safety, and imaging technique&quot;, section on 'Second generation contrast agents'</a> and <a href=\"topic.htm?path=clinical-features-and-diagnosis-of-primary-hepatocellular-carcinoma\" class=\"medical medical_review\">&quot;Clinical features and diagnosis of primary hepatocellular carcinoma&quot;</a>.)</p><p>Ultrasound contrast agents are 1 to 10 microns in size (equal to or smaller than red blood cells) and permit visualization of both the macrovasculature and the microvasculature. The minute bubbles survive transpulmonary passage and recirculate, producing systemic ultrasound enhancement. This is an advantage over larger molecules that are retained in vascular beds [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/1,2,14\" class=\"abstract_t\">1,2,14</a>]. Most ultrasound contrast agents are confined to the vascular space. By contrast, most of the contrast agents used for computed tomography or magnetic resonance imaging (MRI) are rapidly cleared from the blood pool into the extravascular space [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/2\" class=\"abstract_t\">2</a>]. Because ultrasound contrast agents remain within the vascular space, only a small amount of contrast agent is required (typically 1 to 2 mL).</p><p>CEUS permits real-time visualization of contrast-enhancement patterns during all vascular phases (arterial, portal-venous, and late) [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/15\" class=\"abstract_t\">15</a>]. This results in higher temporal resolution than can be achieved with other imaging modalities. The arterial phase provides information on the extent and pattern of the vascular supply. The arterial phase starts 10 to 20 seconds after contrast injection and lasts approximately 25 to 35 seconds. The portal-venous phase starts a few seconds after the arterial phase. It typically lasts until two minutes after contrast injection. The portal-venous phase is followed by the late phase, which lasts until the ultrasound contrast agents are cleared from the circulation (typically four to six minutes). In the case of the contrast agent Sonazoid, it is taken up by Kupffer cells, so there is an additional post-vascular (or Kupffer) phase that starts 10 minutes after injection and lasts for an hour or more [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/1,2,16-19\" class=\"abstract_t\">1,2,16-19</a>]. The images are analogous to those obtained with gadolinium-ethoxybenzyl-diethylenetriamine-enhanced MRI [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/15\" class=\"abstract_t\">15</a>].</p><p class=\"headingAnchor\" id=\"H60347586\"><span class=\"h2\">Additional CEUS imaging techniques</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Dynamic CEUS is a method that evaluates the time intensity curves and, therefore, enhancement characteristics of a lesion [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/6\" class=\"abstract_t\">6</a>]. It can be used to monitor the response of tumors being treated with antiangiogenic or antivascular treatments [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/1,2\" class=\"abstract_t\">1,2</a>]. It is based on time intensity curve analysis (contrast kinetics), dynamic vascular patterns (which demonstrate variability in vascularization within a tumor) [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/20\" class=\"abstract_t\">20</a>], and hepatic vein transit times (which are shortened in the presence of hepatic malignancies, presumably because of intrahepatic shunting, although similar findings may be seen in the setting of cirrhosis) [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/21-25\" class=\"abstract_t\">21-25</a>]. </p><p>Other CEUS techniques that have been developed include real-time three-dimensional CEUS imaging [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/26\" class=\"abstract_t\">26</a>] and contrast-enhanced endoscopic ultrasound of the liver [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/27-29\" class=\"abstract_t\">27-29</a>].</p><p class=\"headingAnchor\" id=\"H60340511\"><span class=\"h1\">ADVANTAGES OF CEUS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Contrast-enhanced ultrasound (CEUS) of the liver has several advantages compared with other imaging modalities, including improved lesion characterization compared with grayscale (B-mode) ultrasound [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/1,2,30-32\" class=\"abstract_t\">1,2,30-32</a>], portability, lack of radiation exposure (which may be of particular importance in patients who require repeated examinations) [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/33,34\" class=\"abstract_t\">33,34</a>], and use of contrast agents that do not contain iodine and are not nephrotoxic [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/31\" class=\"abstract_t\">31</a>]. </p><p>Other advantages of CEUS include [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/35\" class=\"abstract_t\">35</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Most ultrasound contrast agents remain within the vascular space and do not extravasate into the interstitial space, resulting in isolated enhancement of the vascular system. This permits superior depiction of vascular morphology on CEUS compared with either CT or MRI [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/36\" class=\"abstract_t\">36</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>CEUS enhances and defines structural anatomy and can quantify tissue perfusion, even at the capillary level in vessels measuring less than 100 microns in diameter [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/14,37\" class=\"abstract_t\">14,37</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>CEUS can be performed without any previous laboratory testing for renal or liver function.</p><p/><p>Imaging liver tumors with CEUS can give immediate results regarding malignancy, and studies have reported a reduction in time to diagnosis when using CEUS compared with CT or MRI [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/38\" class=\"abstract_t\">38</a>]. A shorter time to diagnosis may result in decreased patient anxiety in the case of benign lesions, and permits swift therapeutic intervention when necessary. In addition, if CEUS is nondiagnostic, it can be used to guide a biopsy, avoiding unnecessary additional imaging.</p><p class=\"headingAnchor\" id=\"H60338228\"><span class=\"h1\">INDICATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Where available, contrast-enhanced ultrasound (CEUS) is used to evaluate focal liver lesions, to guide tissue sampling, to help plan and monitor treatment in patients with hepatic tumors, and to assess patients undergoing liver transplantation. As with other imaging studies, CEUS results must be interpreted taking into account the patient&rsquo;s clinical history, examination, and laboratory findings. </p><p>In the appropriate clinical setting, hemangiomas, focal nodular hyperplasia, focal fatty change, and malignancies (eg, metastases and primary liver tumors) can be diagnosed with confidence if typical enhancement patterns are seen. If the enhancement patterns are atypical or if the examination is technically suboptimal, additional investigation is required (typically contrast-enhanced magnetic resonance imaging [MRI] or liver biopsy) [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/1,2\" class=\"abstract_t\">1,2</a>]. (See <a href=\"#H61240290\" class=\"local\">'Findings associated with specific lesions'</a> below.)</p><p class=\"headingAnchor\" id=\"H60340095\"><span class=\"h2\">Detection and characterization of liver lesions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>CEUS can be used to evaluate focal liver lesions discovered with other imaging modalities, including lesions discovered in patients undergoing surveillance for hepatocellular carcinoma (HCC). (See <a href=\"#H3724156885\" class=\"local\">'CEUS Liver Imaging Reporting and Data System (LI-RADS)'</a> below.) </p><p>CEUS can differentiate benign from malignant lesions in most patients with healthy liver parenchyma and can guide biopsies when needed. CEUS can also be used to detect liver metastases in patients with extrahepatic malignancies.</p><p class=\"headingAnchor\" id=\"H61235368\"><span class=\"h3\">Focal liver lesions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>One of the primary roles for CEUS is for the diagnosis, differential diagnosis, and follow-up of patients with focal liver lesions [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/30,39-42\" class=\"abstract_t\">30,39-42</a>]. In this setting, CEUS has a sensitivity of approximately 95 percent and a specificity of approximately 94 percent for diagnosing malignancy. (See <a href=\"#H57749551\" class=\"local\">'Accuracy'</a> below.) </p><p>CEUS is used to characterize focal liver lesions in the following settings:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A focal liver lesion is incidentally detected with ultrasound.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A nodule is detected in a patient undergoing surveillance for HCC. (See <a href=\"#H3724156885\" class=\"local\">'CEUS Liver Imaging Reporting and Data System (LI-RADS)'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A focal liver lesion is seen on computed tomography (CT) or MRI, but the findings are inconclusive (eg, an indeterminate lesion, especially in nodules not suitable for biopsy).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>To monitor changes in the size and enhancement patterns of a focal liver lesion over time when initial imaging is not diagnostic and the decision has been made to follow the lesion with serial imaging.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>To characterize focal liver lesions with inconclusive cytology or histology following tissue sampling.</p><p/><p>CEUS can also be used to guide biopsies of focal liver lesions. CEUS-guided liver biopsies have a higher diagnostic accuracy than those guided by unenhanced ultrasound. In a study that looked at 107 patients with 140 lesions, CEUS-guided biopsies had a diagnostic accuracy of 95 percent, compared with 87 percent for biopsies guided by unenhanced ultrasound [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/43\" class=\"abstract_t\">43</a>]. This improved accuracy may in part be due to the fact that CEUS can target vascularized (viable) areas of the tumor and avoid areas of necrosis. If there are multiple lesions seen, CEUS can be used to select the most appropriate lesion(s) for biopsy.</p><p class=\"headingAnchor\" id=\"H61235572\"><span class=\"h3\">Liver metastases</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>CEUS is similar to CT and MRI for detecting liver metastases [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/1,2,44-47\" class=\"abstract_t\">1,2,44-47</a>]. The dual blood supply of the liver from the hepatic artery (25 to 30 percent) and the portal vein (70 to 75 percent) permits detection and characterization of focal liver lesions based on vascular enhancement patterns. (See <a href=\"#H60341910\" class=\"local\">'Malignant lesions'</a> below.) </p><p>CEUS improves the detection of metastases in patients with a history of colorectal cancer who are undergoing surveillance [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/48\" class=\"abstract_t\">48</a>]. </p><p class=\"headingAnchor\" id=\"H60340102\"><span class=\"h2\">Treatment planning</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In patients with malignant lesions, CEUS can be used to plan radiofrequency ablation, to assess lesions for resectability, and to help differentiate benign thrombi from neoplastic infiltration of the hepatic vessels.</p><p class=\"headingAnchor\" id=\"H61239833\"><span class=\"h3\">Transcutaneous CEUS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In patients undergoing radiofrequency ablation, CEUS can [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/1,2\" class=\"abstract_t\">1,2</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Complement contrast-enhanced CT or MRI for pretreatment staging and assessment of target lesion vascularity</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Facilitate needle positioning in cases of incomplete or poor lesion delineation on unenhanced ultrasound</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Evaluate the immediate treatment effect after ablation and guide immediate retreatment of residual tumor</p><p/><p>CEUS is also helpful for differentiating between venous thrombosis and tumor infiltration of hepatic vessels. Venous thrombi are avascular, so they are nonenhancing in all phases, whereas neoplastic infiltration displays the same enhancement characteristics as the tumor from which it originated. (See <a href=\"topic.htm?path=chronic-portal-vein-thrombosis-in-adults-clinical-manifestations-diagnosis-and-management#H417348800\" class=\"medical medical_review\">&quot;Chronic portal vein thrombosis in adults: Clinical manifestations, diagnosis, and management&quot;, section on 'Differential diagnosis'</a>.)</p><p class=\"headingAnchor\" id=\"H61239827\"><span class=\"h3\">Intraoperative CEUS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Intraoperative CEUS can be used to determine whether a hepatic tumor (either a primary tumor or metastatic lesion) is resectable [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/17,19,49-51\" class=\"abstract_t\">17,19,49-51</a>]. It is also used to characterize nodules detected with unenhanced intraoperative ultrasound in patients with cirrhosis who are undergoing liver resection for HCC [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/1,2\" class=\"abstract_t\">1,2</a>]. </p><p>Studies suggest that intraoperative CEUS is more sensitive, specific, and accurate than unenhanced intraoperative ultrasound, contrast-enhanced CT, or contrast-enhanced MRI for assessing tumor resectability [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/51\" class=\"abstract_t\">51</a>], and that CEUS leads to a change in surgical management in up to 30 percent of cases [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/2,49-51\" class=\"abstract_t\">2,49-51</a>]. However, in practice, positioning of the transducer may be more difficult than has been described in studies.</p><p class=\"headingAnchor\" id=\"H60340127\"><span class=\"h2\">Treatment monitoring</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with liver tumors that are being treated with ablation or <span class=\"nowrap\">chemotherapy/radioembolization</span> need follow-up imaging to assess the initial treatment response and to look for signs of tumor progression (<a href=\"image.htm?imageKey=GAST%2F96803\" class=\"graphic graphic_diagnosticimage graphicRef96803 \">image 1</a>) [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/1,2\" class=\"abstract_t\">1,2</a>]. CEUS can be used if contrast-enhanced CT or MRI are inconclusive, to avoid radiation exposure, or in addition to CT or MRI. (See <a href=\"topic.htm?path=assessment-of-tumor-response-in-patients-receiving-systemic-and-nonsurgical-locoregional-treatment-of-hepatocellular-cancer\" class=\"medical medical_review\">&quot;Assessment of tumor response in patients receiving systemic and nonsurgical locoregional treatment of hepatocellular cancer&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H60340208\"><span class=\"h2\">Liver transplantation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Prior to liver transplantation, CEUS can be used to rapidly assess patency of the hepatic artery and portal vein and to characterize focal liver lesions. CEUS can be helpful in the post-surgical phase to detect vascular complications noninvasively, particularly at the bedside or in the intensive care unit, avoiding most of the risks associated with contrast-enhanced CT or angiography.</p><p class=\"headingAnchor\" id=\"H60340352\"><span class=\"h2\">Other diagnostic and therapeutic uses</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>CEUS can also be used to [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/1,2\" class=\"abstract_t\">1,2</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Evaluate vascular lesions, such as aneurysms and pseudoaneurysms of the hepatic arteries</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Diagnose liver infarction in patients with sickle cell anemia</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Guide percutaneous transhepatic cholangiography and drainage [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/52\" class=\"abstract_t\">52</a>] </p><p/><p class=\"headingAnchor\" id=\"H57749551\"><span class=\"h1\">ACCURACY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Studies looking at CEUS for the characterization of focal liver lesions have estimated that CEUS has a sensitivity of approximately 95 percent and a specificity of approximately 94 percent for diagnosing malignancy [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/53-57\" class=\"abstract_t\">53-57</a>]. Studies also suggest that CEUS is similar (or possibly superior) to contrast-enhanced computed tomography (CT) and contrast-enhanced magnetic resonance imaging (MRI) for the diagnosis of focal liver lesions [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/31,44,45,53-55,58-63\" class=\"abstract_t\">31,44,45,53-55,58-63</a>]. </p><p>A meta-analysis of 21 studies (22 publications) compared CEUS with other imaging modalities for a variety of indications [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/54\" class=\"abstract_t\">54</a>]. Using variable diagnostic criteria, the sensitivity for diagnosing malignancy was 27 to 98 percent for CEUS, 47 to 98 percent for contrast-enhanced CT, and 44 to 97 percent for contrast-enhanced MRI. Sensitivities were generally lower for small lesions compared with larger lesions. Specificities were 50 to 100 percent, 71 to 100 percent, and 62 to 100 percent, respectively. For incidentally detected liver lesions, the pooled sensitivity for CEUS was 95 percent (95% CI 93-97 percent) and for CT was 95 percent (95% CI 93-96 percent), based on the data from four studies. The pooled specificity for CEUS was 94 percent (95% CI 90-96 percent) and for CT was 93 percent (95% CI 90-96 percent).</p><p>Discordant findings between CEUS and contrast-enhanced CT could occur for several reasons, including differences in timing of contrast administration and imaging, diffusion of contrast, and the influence of fat on lesion characterization [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/56,64\" class=\"abstract_t\">56,64</a>]. With CEUS, the bolus of microbubbles (1.2 to 4.8 mL) is administered over a few seconds, which may be more temporally sensitive than the larger volume CT contrast agent (140 mL) injected over 40 seconds. In addition, diffusion into the interstitium of the contrast agent used for CT and the subsequent slow wash-out can result in erroneous diagnoses based on portal-venous phase enhancement patterns. Portal-venous phase wash-out that is evident with CEUS may not be apparent with contrast-enhanced CT. In addition, the predetermined scan delay in contrast-enhanced CT can miss the rapid initial wash-in and arterial phase hypervascular response that can be seen with CEUS, which acquires images in real-time. (See <a href=\"#H60347672\" class=\"local\">'Standard CEUS'</a> above.)</p><p>The fat content of the liver lesion and surrounding parenchyma may also result in discordant results between CEUS and contrast-enhanced CT. Fat is echogenic and can attenuate the difference in appearance between the microbubbles and the tissue, making lesion characterization with CEUS more difficult [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/64\" class=\"abstract_t\">64</a>].</p><p class=\"headingAnchor\" id=\"H61240290\"><span class=\"h1\">FINDINGS ASSOCIATED WITH SPECIFIC LESIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Liver lesion characterization is based on real-time evaluation of contrast enhancement of the lesion (hypoenhancing, isoenhancing, hyperenhancing) compared with the surrounding liver parenchyma. It is assessed during the arterial phase, portal-venous phase, and late phase. </p><p>Characterization starts by assessing the initial pattern of contrast enhancement within the lesion (central or peripheral) and specific vascularization patterns (eg, wheel-spoke pattern, nodular or rim enhancement, diffuse enhancement) seen in the arterial and portal-venous phases. Vascularization patterns are helpful because benign lesions (except cysts and calcifications) contain, in addition to hepatic arteries, liver-specific portal veins and sinusoids [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/31,65\" class=\"abstract_t\">31,65</a>]. </p><p>Enhancement patterns during the portal-venous and late phases provide additional important information for characterizing liver lesions; typically, malignant lesions are hypoenhancing (<a href=\"image.htm?imageKey=GAST%2F96791\" class=\"graphic graphic_diagnosticimage graphicRef96791 \">image 2</a>), whereas the majority of solid, benign lesions are isoenhancing or hyperenhancing [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/1,2,66,67\" class=\"abstract_t\">1,2,66,67</a>].</p><p class=\"headingAnchor\" id=\"H60343227\"><span class=\"h2\">Benign lesions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Benign liver lesions that can be characterized by contrast-enhanced ultrasound (CEUS) include hemangiomas, focal nodular hyperplasia (FNH), hepatic adenomas, focal fatty infiltration, abscesses, and hematomas. </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Hemangiomas</strong> &ndash; CEUS improves the rate of correct diagnosis of hemangiomas from approximately 75 percent with unenhanced ultrasound to more than 95 percent [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/2,56,68\" class=\"abstract_t\">2,56,68</a>]. In hemangiomas, the most common findings on CEUS are peripheral nodular enhancement in the arterial phase, followed by partial or complete centripetal fill-in (the iris diaphragm phenomenon) (<a href=\"image.htm?imageKey=GAST%2F96792\" class=\"graphic graphic_diagnosticimage graphicRef96792 \">image 3</a> and <a href=\"image.htm?imageKey=GAST%2F96793\" class=\"graphic graphic_table graphicRef96793 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/15\" class=\"abstract_t\">15</a>]. Enhancement is sustained through the late phase and, if Sonazoid was used as the contrast agent, through the post-vascular phase. (See <a href=\"#H60347672\" class=\"local\">'Standard CEUS'</a> above.)</p><p/><p class=\"bulletIndent1\">Atypical features include [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/15\" class=\"abstract_t\">15</a>]:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Incomplete late filing in large (&gt;4 cm) hemangiomas.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>&quot;Shunt hemangiomas&quot; (functionally described as high-flow hemangiomas): These hemangiomas show rapid enhancement during the arterial phase (in a peripheral nodular pattern), markedly hypervascular appearance, and arterio-portovenous shunts with early opacification of the draining portal vein [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/68,69\" class=\"abstract_t\">68,69</a>]. Shunt hemangiomas are typically surrounded by focal hypoechoic areas, which represent reduced fat content in comparison with the surrounding liver parenchyma [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/68\" class=\"abstract_t\">68</a>]. The reduced fat content may be explained by a mainly arterial blood supply of the hypoechoic areas, whereas blood supply of the surrounding liver parenchyma is mainly by portal vessels that contain more lipids and insulin. Shunt hemangiomas can be mistaken for hepatocellular carcinoma (HCC) or FNH.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Sclerosing hemangiomas with abundant regressive changes and thrombosis.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Focal nodular hyperplasia</strong> &ndash; The CEUS characteristics seen with focal nodular hyperplasia (FNH) reflect its central or eccentric vascular supply (<a href=\"image.htm?imageKey=GAST%2F96795\" class=\"graphic graphic_diagnosticimage graphicRef96795 \">image 4</a>). FNH is hyperenhancing in the arterial and portal-venous phases in more than 90 percent of cases [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/70\" class=\"abstract_t\">70</a>] (<a href=\"image.htm?imageKey=GAST%2F96796\" class=\"graphic graphic_table graphicRef96796 \">table 2</a>). False hypoenhancement can sometimes be observed due to bubble destruction. Fill-in starts from the center of the lesion and then spreads outward in a wheel-spoke pattern. In the late phase, the perfusion pattern is typically hyperechoic or isoechoic.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Hepatic adenomas</strong> &ndash; Hepatic adenomas typically show rapid arterial hyperenhancement that progresses from the periphery to the center (<a href=\"image.htm?imageKey=GAST%2F96802\" class=\"graphic graphic_diagnosticimage graphicRef96802 \">image 5</a>) [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/15,71-73\" class=\"abstract_t\">15,71-73</a>]. This pattern is also found in HCC and metastases, but is the opposite of what is seen in FNH, in which filling starts centrally and moves peripherally. In the late phase, there is gradual washout due to missing portal veins. Hemorrhagic areas are avascular and thus do not enhance in any phase.</p><p/><p class=\"bulletIndent1\">Glycogen storage disease-associated hepatic adenomas typically show slight hypoenhancement in the portal-venous phase [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/71\" class=\"abstract_t\">71</a>], whereas telangiectatic lesions may show hyperenhancement. In the case of portal-venous hypoenhancement, biopsy is required to make the diagnosis. In the case of suspected hepatic adenoma, biopsy should include surrounding liver parenchyma to look for liver storage disease with associated hepatic adenoma. Cholangiocellular adenomas also show hypoenhancement in the portal-venous phase [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/74\" class=\"abstract_t\">74</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Focal fatty lesions (focal fatty infiltration)</strong> &ndash; Focal fatty changes (either fat infiltration or fatty sparing) are typical features of hepatic steatosis. They may simulate neoplasia on unenhanced ultrasound [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/4\" class=\"abstract_t\">4</a>]. In the arterial, portal-venous, and late phases, focal fatty changes show similar enhancement patterns to those of the adjacent liver parenchyma [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/1,2\" class=\"abstract_t\">1,2</a>]. Typically, centrally located arteries can be identified in focal fatty sparing [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/75-77\" class=\"abstract_t\">75-77</a>], explaining the relatively lower fat concentration in such areas (arterial blood contains less lipids and insulin than blood from the portal vein). In focal fatty infiltration, portal-venous branches enter from the liver hilum and account for the higher fat concentration in such areas. Focal fatty sparing seen on ultrasound examination may be a sign of an adjacent focal liver lesion, so additional lesions should be sought during the CEUS examination [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/78,79\" class=\"abstract_t\">78,79</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Abscess</strong> &ndash; Phlegmonous inflammation is sometimes confusing since it changes over time. Early lesions are hyperenhancing, while mature lesions develop hypo- or nonenhancing foci. Mature abscesses typically show marginal enhancement in the arterial phase. However, enhancement of septae followed by portal-venous hypoenhancement may also be seen. The most prominent feature is lack of enhancement in the liquefied portions [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/2,80-82\" class=\"abstract_t\">2,80-82</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Hematoma</strong> &ndash; Circumscribed hematomas or diffuse (subcapsular) hemorrhages of the liver and spleen are most often a consequence of trauma [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/83-85\" class=\"abstract_t\">83-85</a>]. CEUS has been proven to be especially helpful in the emergency setting [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/5,86\" class=\"abstract_t\">5,86</a>]. Since ultrasound contrast agents are intravascular, it is easy to identify hematomas, which are nonenhancing. Computer tomography (CT) contrast agents, on the other hand, diffuse into the surrounding extravascular spaces. CEUS can also detect active bleeding by visualizing echoes within the collection and detecting possible vascular malformations that can cause bleeding [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/87\" class=\"abstract_t\">87</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Other benign focal liver lesions</strong> &ndash; The use of CEUS has been described in case reports and case series with cystadenomas [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/88-90\" class=\"abstract_t\">88-90</a>] inflammatory pseudotumors [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/91\" class=\"abstract_t\">91</a>], fasciola hepatica [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/92\" class=\"abstract_t\">92</a>], granulomas [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/32,93\" class=\"abstract_t\">32,93</a>], tuberculosis [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/94\" class=\"abstract_t\">94</a>], sarcoidosis [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/95-97\" class=\"abstract_t\">95-97</a>], nodules in Wilson disease, peliosis hepatis [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/98-100\" class=\"abstract_t\">98-100</a>], angiomyolipomas [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/101,102\" class=\"abstract_t\">101,102</a>], hemangioendotheliomas [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/38,103\" class=\"abstract_t\">38,103</a>], angiosarcomas of the liver [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/104\" class=\"abstract_t\">104</a>], liver actinomycosis [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/105\" class=\"abstract_t\">105</a>], hamartomas [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/106\" class=\"abstract_t\">106</a>], nodular regenerative hyperplasia [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/107\" class=\"abstract_t\">107</a>], echinococcosis [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/108\" class=\"abstract_t\">108</a>], sickle cell anemia with liver infarction, bartonellosis [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/109\" class=\"abstract_t\">109</a>], and pseudoaneurysms of hepatic arteries [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/110\" class=\"abstract_t\">110</a>] and portal veins [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/111\" class=\"abstract_t\">111</a>].</p><p/><p class=\"headingAnchor\" id=\"H60341910\"><span class=\"h2\">Malignant lesions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>CEUS can detect malignant liver lesions such as HCC, cholangiocarcinoma, metastatic lesions, and lymphoma. Malignant focal liver lesions appear variably as hyper-, iso-, or hypoenhancing lesions during the arterial phase, and as hypoenhancing during the portal-venous and late phases. </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Hepatocellular carcinoma</strong> &ndash; The appearance of HCC varies depending on whether the patient has cirrhosis.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Patients without cirrhosis &ndash; </strong>HCC in the noncirrhotic liver is typically hyperenhancing in the arterial phase with a chaotic vascular pattern, and hypoenhancing in the portal-venous and late phases (<a href=\"image.htm?imageKey=GAST%2F96791\" class=\"graphic graphic_diagnosticimage graphicRef96791 \">image 2</a>) [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/1,2,72,112,113\" class=\"abstract_t\">1,2,72,112,113</a>]. However, well-differentiated (borderline) HCC is less likely to show arterial enhancement and is more likely to be isoenhancing in the late phase [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/15\" class=\"abstract_t\">15</a>]. During the post-vascular phase (if Sonazoid is used as the contrast agent), HCC is typically hypoenhancing, which helps differentiate it from benign lesions that are iso- or hyperenhancing.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Patients with cirrhosis &ndash; </strong>The development of HCC in patients with cirrhosis is explained by a multistep pathway [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/114-116\" class=\"abstract_t\">114-116</a>], from regenerative nodule, low- or high-grade dysplastic nodule, dysplastic nodule with a focus of HCC, well-differentiated HCC, and finally moderately to poorly differentiated HCC. Progression along this pathway is accompanied by a decrease in both normal arterial and portal blood flow and is characterized by a progressive increase in arterial flow from newly formed tumor vessels (neoangiogenesis) and a concurrent disappearance of normal intranodular vessels. Therefore, hyperenhancement in the arterial phase can be seen in HCC of all stages of differentiation [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/1,2\" class=\"abstract_t\">1,2</a>].</p><p/><p class=\"bulletIndent2\">HCC shows homogenous (non-rim-like) arterial enhancement, especially in smaller lesions (&lt;50 mm), with nonenhancing areas in larger lesions due to hemorrhage, necrosis, and calcifications. Atypical neoplastic vessels can be displayed in the arterial phase by their short course and tortuous pattern. The enhancement pattern in the portal-venous phase depends on the vascularity of the surrounding cirrhotic liver parenchyma, with most lesions showing mild hypoenhancement that is late in onset (&gt;60 sec). Some HCCs do not demonstrate wash-out until three to four minutes after contrast injection. Studies with extended late phases have demonstrated that the timing of HCC wash-out correlates with tumor differentiation [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/117-122\" class=\"abstract_t\">117-122</a>]. Well-differentiated HCCs wash out more slowly than poorly differentiated tumors. Therefore, it is recommended that the CEUS protocol extend to at least four minutes to ensure that hypoenhancement is not missed. By contrast, regenerative and dysplastic nodules are typically isoenhancing in all phases.</p><p/><p class=\"headingAnchor\" id=\"H3724156885\"><span class=\"h3\">CEUS Liver Imaging Reporting and Data System (LI-RADS)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Following the FDA approval of the ultrasound contrast agent Lumason (<a href=\"topic.htm?path=sulfur-hexafluoride-lipid-microspheres-drug-information\" class=\"drug drug_general\">sulfur hexafluoride lipid microspheres</a>) for assessment of focal liver lesions in 2016, the American College of Radiology (ACR) endorsed a proposed <a href=\"https://www.acr.org/Quality-Safety/Resources/LIRADS&amp;token=IQxLzDq4doJGUgaZgeIY02oiK5qwhYkksaXHqb5gHKJCE7W3vXnfl2dEFnEJE64Y7bx8lN52/PBj9r4V+MtY0Q==&amp;TOPIC_ID=96352\" target=\"_blank\" class=\"external\">Liver Imaging Reporting and Data System (LI-RADS)</a> classification system for estimating the likelihood of HCC in at-risk patients based upon CEUS (CEUS LI-RADS v2016). Lesions are classified from 'definitely benign' (LR-1) to 'definitely HCC' (LR-5) based upon specific imaging criteria [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/123\" class=\"abstract_t\">123</a>]. With use of the algorithm, LI-RADS provides standardized terminology, interpretation, and reporting of CEUS in at-risk patients and is not intended for use in the general population. </p><p>The key feature of CEUS in the diagnosis of hepatocellular carcinoma (HCC) in patients with cirrhosis is the detection of hyperenhancement of the nodule in comparison to the surrounding parenchyma in the arterial phase (whole or in part, not globular or rim-like), followed by washout in the late phase (late in onset &ge; 60 sec and mild in degree), when the nodule becomes hypoenhanced in comparison to the surrounding parenchyma. Sonographically distinct solid nodules &ge;10 mm in diameter may be diagnosed as definite HCC (CEUS LR-5) if they show both of the mentioned two criteria [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/123\" class=\"abstract_t\">123</a>]. </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Intrahepatic cholangiocarcinoma</strong> &ndash; The typical CEUS pattern seen with intrahepatic cholangiocarcinomas is peripheral, rim-like contrast enhancement in the arterial phase and early hypoenhancement in the portal-venous and late phases, irrespective of whether the liver parenchyma is cirrhotic. This differs from the homogenous (non-rim-like) arterial enhancement of HCC, which often demonstrates isoenhancement during the later phases in liver cirrhosis [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/67,124\" class=\"abstract_t\">67,124</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Metastases</strong> &ndash; Liver metastases show various contrast enhancement patterns during the arterial phase and are almost always hypoenhancing during the portal-venous and late phases [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/15\" class=\"abstract_t\">15</a>]. CEUS is particularly sensitive for detecting metastases from neuroendocrine tumors [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/125,126\" class=\"abstract_t\">125,126</a>]. If neuroendocrine tumor metastases are suspected, the CEUS evaluation should be prolonged up to five minutes [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/125,127\" class=\"abstract_t\">125,127</a>]. False-negative findings are mainly explained by rarefaction of portal vein branches in the surrounding liver parenchyma, which may occur in severe, diffuse liver disease. False-positive findings are seen with focal inflammation, abscess, necrosis, fibrous tissue, and scarring. Since hypoenhancing lesions have to be biopsied for histologic confirmation, false-positive lesions are generally not a clinically significant problem.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Lymphoma</strong> &ndash; Lymphoma shows variable arterial enhancement, depending on the underlying entity, and characteristic hypoenhancement in the portal-venous and late phases.</p><p/><p class=\"headingAnchor\" id=\"H92235833\"><span class=\"h1\">SAFETY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Ultrasound contrast agents are safe, with a very low incidence of side effects [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/1,2,128,129\" class=\"abstract_t\">1,2,128,129</a>]. In the United States, the contrast agent <a href=\"topic.htm?path=sulfur-hexafluoride-lipid-microspheres-drug-information\" class=\"drug drug_general\">sulfur hexafluoride lipid microspheres</a> (Lumason) contains a boxed warning regarding the risk of rare but serious cardiopulmonary reactions and hypersensitivity reactions [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/130\" class=\"abstract_t\">130</a>]. Patients should be assessed for conditions that preclude administration, and resuscitation equipment and trained personnel should be on site. The incidence of severe hypersensitivity events is lower than with iodinated contrast agents and is comparable to those encountered with magnetic resonance imaging contrast agents [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/1,2,128\" class=\"abstract_t\">1,2,128</a>].</p><p>There are no hepatotoxic or nephrotoxic effects of ultrasound contrast agents. Therefore, it is not necessary to perform laboratory tests to assess liver or kidney function before administration. </p><p>Although Lumason (<a href=\"topic.htm?path=sulfur-hexafluoride-lipid-microspheres-drug-information\" class=\"drug drug_general\">sulfur hexafluoride lipid microspheres</a>) has been approved by the FDA for use in adult and pediatric patients [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/131,132\" class=\"abstract_t\">131,132</a>], there are limited data on the use of ultrasound contrast agents in pregnancy and during breastfeeding [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/1,2,133\" class=\"abstract_t\">1,2,133</a>]. We will use CEUS if clinically indicated after explaining to the patient and parent that data on CEUS in this setting are limited and after obtaining informed consent.</p><p class=\"headingAnchor\" id=\"H61243670\"><span class=\"h1\">LIMITATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Limitations of contrast-enhanced ultrasound (CEUS) include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The smallest detectable lesions are typically between 3 and 5 mm in diameter. As a result, small focal liver lesions may be missed.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Limited penetration into the liver, so deep lesions may not be seen. This is particularly a problem in the setting of steatosis. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Subdiaphragmatic lesions in liver segments 7 and 8 may not be accessible. This limitation can be minimized by performing intercostal scanning and positioning the patient in the left decubitus or standing position.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The falciform ligament and surrounding fat may be confused with a focal liver lesion.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>False-positive findings may be seen with scars and fibrosis, necrosis, phlegmonous infiltration, sarcoidosis, and inflammatory pseudotumors of the liver [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/75,134\" class=\"abstract_t\">75,134</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>It can be difficult to position the probe for intraoperative CEUS. In addition, intraoperative CEUS may be limited by the relatively short duration of contrast enhancement [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/49\" class=\"abstract_t\">49</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In patients with cirrhosis, benign liver lesions can be difficult to diagnose since the portal vein branches are reduced in favor of a more arterial vascular supply [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/135,136\" class=\"abstract_t\">135,136</a>]. Focal nodular hyperplasia can be particularly difficult to diagnose in patients with cirrhosis. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Bubble destruction and shadowing may result in artifacts [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/75,134,137\" class=\"abstract_t\">75,134,137</a>].</p><p/><p class=\"headingAnchor\" id=\"H61243901\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Contrast-enhanced ultrasound (CEUS) is a technique for imaging the liver and other organs. It is used most frequently in Europe and Asia, as well as in other countries worldwide. The contrast agent, Lumason (<a href=\"topic.htm?path=sulfur-hexafluoride-lipid-microspheres-drug-information\" class=\"drug drug_general\">sulfur hexafluoride lipid microspheres</a>) was approved in 2016 by the US Food and Drug Administration for the examination of the liver in adults and pediatric patients. (See <a href=\"#H92235595\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>CEUS uses ultrasound contrast agents to improve visualization and characterization of anatomic structures and lesions. It is most often performed transcutaneously, though it can also be used intraoperatively. Ultrasound contrast agents are microbubbles consisting of gas bubbles stabilized by a shell. They are 1 to 10 microns in size (equal to or smaller than red blood cells) and permit visualization of both the macrovasculature and the microvasculature. The minute bubbles survive transpulmonary passage and recirculate, producing systemic ultrasound enhancement. (See <a href=\"#H60347672\" class=\"local\">'Standard CEUS'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>CEUS permits real-time visualization of contrast-enhancement patterns during all vascular phases (arterial, portal-venous, and late). This results in higher temporal resolution than can be achieved with other imaging modalities. (See <a href=\"#H60347672\" class=\"local\">'Standard CEUS'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>CEUS of the liver has several advantages compared with other imaging modalities, including improved lesion characterization compared with grayscale (B-mode) ultrasound, portability, lack of radiation exposure (which may be of particular importance in patients who require repeated examinations), and use of contrast agents that do not contain iodine and are not nephrotoxic &#160; (See <a href=\"#H60340511\" class=\"local\">'Advantages of CEUS'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>CEUS is used to evaluate focal liver lesions, to guide tissue sampling, and to help plan and monitor treatment in patients with hepatic tumors. In the appropriate clinical setting, hemangiomas, focal nodular hyperplasia, focal fatty change, and malignancies can be diagnosed with confidence if typical enhancement patterns are seen. If the enhancement patterns are atypical or if the examination is technically suboptimal, additional investigation is required. (See <a href=\"#H60338228\" class=\"local\">'Indications'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>CEUS has an estimated sensitivity of approximately 95 percent and a specificity of approximately 94 percent for diagnosing malignancy. It also appears to be similar (or possibly superior) to contrast-enhanced CT and contrast-enhanced MRI for the diagnosis of focal liver lesions. (See <a href=\"#H57749551\" class=\"local\">'Accuracy'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/1\" class=\"nounderline abstract_t\">Claudon M, Dietrich CF, Choi BI, et al. Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver - update 2012: A WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultrasound Med Biol 2013; 39:187.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/2\" class=\"nounderline abstract_t\">Claudon M, Dietrich CF, Choi BI, et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver--update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultraschall Med 2013; 34:11.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/3\" class=\"nounderline abstract_t\">Albrecht T, Blomley M, Bolondi L, et al. Guidelines for the use of contrast agents in ultrasound. January 2004. Ultraschall Med 2004; 25:249.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/4\" class=\"nounderline abstract_t\">Claudon M, Cosgrove D, Albrecht T, et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) - update 2008. Ultraschall Med 2008; 29:28.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/5\" class=\"nounderline abstract_t\">Piscaglia F, Nols&oslash;e C, Dietrich CF, et al. The EFSUMB Guidelines and Recommendations on the Clinical Practice of Contrast Enhanced Ultrasound (CEUS): update 2011 on non-hepatic applications. Ultraschall Med 2012; 33:33.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/6\" class=\"nounderline abstract_t\">Dietrich CF, Averkiou MA, Correas JM, et al. An EFSUMB introduction into Dynamic Contrast-Enhanced Ultrasound (DCE-US) for quantification of tumour perfusion. Ultraschall Med 2012; 33:344.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/7\" class=\"nounderline abstract_t\">Sidhu PS, Brabrand K, Cantisani V, et al. EFSUMB Guidelines on Interventional Ultrasound (INVUS), Part II. Diagnostic Ultrasound-Guided Interventional Procedures (Long Version). Ultraschall Med 2015; 36:E15.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/8\" class=\"nounderline abstract_t\">Lorentzen T, Nols&oslash;e CP, Ewertsen C, et al. EFSUMB Guidelines on Interventional Ultrasound (INVUS), Part I. General Aspects (long Version). Ultraschall Med 2015; 36:E1.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/9\" class=\"nounderline abstract_t\">Sidhu PS, Brabrand K, Cantisani V, et al. EFSUMB Guidelines on Interventional Ultrasound (INVUS), Part II. Diagnostic Ultrasound-Guided Interventional Procedures (Short Version). Ultraschall Med 2015; 36:566.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/10\" class=\"nounderline abstract_t\">Dietrich CF, Lorentzen T, Appelbaum L, et al. EFSUMB Guidelines on Interventional Ultrasound (INVUS), Part III - Abdominal Treatment Procedures (Short Version). Ultraschall Med 2016; 37:27.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/11\" class=\"nounderline abstract_t\">Dietrich CF, Lorentzen T, Sidhu PS, et al. An Introduction to the EFSUMB Guidelines on Interventional Ultrasound (INVUS). Ultraschall Med 2015; 36:460.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/12\" class=\"nounderline abstract_t\">Lorentzen T, Nols&oslash;e CP, Ewertsen C, et al. EFSUMB Guidelines on Interventional Ultrasound (INVUS), Part I. General Aspects (Short Version). Ultraschall Med 2015; 36:464.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/13\" class=\"nounderline abstract_t\">Dietrich CF, Lorentzen T, Appelbaum L, et al. EFSUMB Guidelines on Interventional Ultrasound (INVUS), Part III - Abdominal Treatment Procedures (Long Version). Ultraschall Med 2016; 37:E1.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/14\" class=\"nounderline abstract_t\">Granada JF, Feinstein SB. Imaging of the vasa vasorum. Nat Clin Pract Cardiovasc Med 2008; 5 Suppl 2:S18.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/15\" class=\"nounderline abstract_t\">Jang JY, Kim MY, Jeong SW, et al. Current consensus and guidelines of contrast enhanced ultrasound for the characterization of focal liver lesions. Clin Mol Hepatol 2013; 19:1.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/16\" class=\"nounderline abstract_t\">Maruyama H, Takahashi M, Ishibashi H, et al. Contrast-enhanced ultrasound for characterisation of hepatic lesions appearing non-hypervascular on CT in chronic liver diseases. Br J Radiol 2012; 85:351.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/17\" class=\"nounderline abstract_t\">Arita J, Hasegawa K, Takahashi M, et al. Correlation between contrast-enhanced intraoperative ultrasound using Sonazoid and histologic grade of resected hepatocellular carcinoma. AJR Am J Roentgenol 2011; 196:1314.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/18\" class=\"nounderline abstract_t\">Salvatore V, Borghi A, Piscaglia F. Contrast-enhanced ultrasound for liver imaging: recent advances. Curr Pharm Des 2012; 18:2236.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/19\" class=\"nounderline abstract_t\">Nakano H, Ishida Y, Hatakeyama T, et al. Contrast-enhanced intraoperative ultrasonography equipped with late Kupffer-phase image obtained by sonazoid in patients with colorectal liver metastases. World J Gastroenterol 2008; 14:3207.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/20\" class=\"nounderline abstract_t\">Cui XW, Ignee A, Jedrzejczyk M, Dietrich CF. Dynamic Vascular Pattern (DVP), a quantification tool for contrast enhanced ultrasound. Z Gastroenterol 2013; 51:427.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/21\" class=\"nounderline abstract_t\">Blomley MJ, Albrecht T, Cosgrove DO, et al. Liver vascular transit time analyzed with dynamic hepatic venography with bolus injections of an US contrast agent: early experience in seven patients with metastases. Radiology 1998; 209:862.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/22\" class=\"nounderline abstract_t\">Tang A, Kim TK, Heathcote J, et al. Does hepatic vein transit time performed with contrast-enhanced ultrasound predict the severity of hepatic fibrosis? Ultrasound Med Biol 2011; 37:1963.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/23\" class=\"nounderline abstract_t\">Zhou X, Strobel D, Haensler J, Bernatik T. Hepatic transit time: indicator of the therapeutic response to radiofrequency ablation of liver tumours. Br J Radiol 2005; 78:433.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/24\" class=\"nounderline abstract_t\">Bernatik T, Becker D, Neureiter D, et al. Hepatic transit time of an echo enhancer: an indicator of metastatic spread to the liver. Eur J Gastroenterol Hepatol 2004; 16:313.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/25\" class=\"nounderline abstract_t\">Fr&ouml;hlich E, Muller R, Cui XW, et al. Dynamic contrast-enhanced ultrasound for quantification of tissue perfusion. J Ultrasound Med 2015; 34:179.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/26\" class=\"nounderline abstract_t\">Dietrich CF. [3D real time contrast enhanced ultrasonography,a new technique]. Rofo 2002; 174:160.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/27\" class=\"nounderline abstract_t\">Dietrich CF. Contrast-enhanced low mechanical index endoscopic ultrasound (CELMI-EUS). Endoscopy 2009; 41 Suppl 2:E43.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/28\" class=\"nounderline abstract_t\">Dietrich CF, Ignee A, Frey H. Contrast-enhanced endoscopic ultrasound with low mechanical index: a new technique. Z Gastroenterol 2005; 43:1219.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/29\" class=\"nounderline abstract_t\">Dietrich CF, Dong Y, Froehlich E, Hocke M. Dynamic contrast-enhanced endoscopic ultrasound: A quantification method. Endosc Ultrasound 2016.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/30\" class=\"nounderline abstract_t\">Wilson SR, Burns PN. An algorithm for the diagnosis of focal liver masses using microbubble contrast-enhanced pulse-inversion sonography. AJR Am J Roentgenol 2006; 186:1401.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/31\" class=\"nounderline abstract_t\">Strobel D, Seitz K, Blank W, et al. Contrast-enhanced ultrasound for the characterization of focal liver lesions--diagnostic accuracy in clinical practice (DEGUM multicenter trial). Ultraschall Med 2008; 29:499.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/32\" class=\"nounderline abstract_t\">Dietrich CF, Ignee A, Trojan J, et al. Improved characterisation of histologically proven liver tumours by contrast enhanced ultrasonography during the portal venous and specific late phase of SHU 508A. Gut 2004; 53:401.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/33\" class=\"nounderline abstract_t\">Brenner DJ, Hall EJ. Computed tomography--an increasing source of radiation exposure. N Engl J Med 2007; 357:2277.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/34\" class=\"nounderline abstract_t\">Hricak H, Brenner DJ, Adelstein SJ, et al. Managing radiation use in medical imaging: a multifaceted challenge. Radiology 2011; 258:889.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/35\" class=\"nounderline abstract_t\">Wilson SR, Greenbaum LD, Goldberg BB. Contrast-enhanced ultrasound: what is the evidence and what are the obstacles? AJR Am J Roentgenol 2009; 193:55.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/36\" class=\"nounderline abstract_t\">Wilson SR, Jang HJ, Kim TK, et al. Real-time temporal maximum-intensity-projection imaging of hepatic lesions with contrast-enhanced sonography. AJR Am J Roentgenol 2008; 190:691.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/37\" class=\"nounderline abstract_t\">Schinkel AF, Krueger CG, Tellez A, et al. Contrast-enhanced ultrasound for imaging vasa vasorum: comparison with histopathology in a swine model of atherosclerosis. Eur J Echocardiogr 2010; 11:659.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/38\" class=\"nounderline abstract_t\">Lanka B, Jang HJ, Kim TK, et al. Impact of contrast-enhanced ultrasonography in a tertiary clinical practice. J Ultrasound Med 2007; 26:1703.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/39\" class=\"nounderline abstract_t\">Leen E, Ceccotti P, Kalogeropoulou C, et al. Prospective multicenter trial evaluating a novel method of characterizing focal liver lesions using contrast-enhanced sonography. AJR Am J Roentgenol 2006; 186:1551.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/40\" class=\"nounderline abstract_t\">Ding H, Wang WP, Huang BJ, et al. Imaging of focal liver lesions: low-mechanical-index real-time ultrasonography with SonoVue. J Ultrasound Med 2005; 24:285.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/41\" class=\"nounderline abstract_t\">Quaia E, Degobbis F, Tona G, et al. [Differential patterns of contrast enhancement in different focal liver lesions after injection of the microbubble US contrast agent SonoVue]. Radiol Med 2004; 107:155.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/42\" class=\"nounderline abstract_t\">Wilson SR, Jang HJ, Kim TK, Burns PN. Diagnosis of focal liver masses on ultrasonography: comparison of unenhanced and contrast-enhanced scans. J Ultrasound Med 2007; 26:775.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/43\" class=\"nounderline abstract_t\">Wu W, Chen MH, Yin SS, et al. The role of contrast-enhanced sonography of focal liver lesions before percutaneous biopsy. AJR Am J Roentgenol 2006; 187:752.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/44\" class=\"nounderline abstract_t\">Dietrich CF, Kratzer W, Strobe D, et al. Assessment of metastatic liver disease in patients with primary extrahepatic tumors by contrast-enhanced sonography versus CT and MRI. World J Gastroenterol 2006; 12:1699.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/45\" class=\"nounderline abstract_t\">Hohmann J, M&uuml;ller A, Skrok J, et al. Detection of hepatocellular carcinoma and liver metastases with BR14: a multicenter phase IIA study. Ultrasound Med Biol 2012; 38:377.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/46\" class=\"nounderline abstract_t\">Correas JM, Low G, Needleman L, et al. Contrast enhanced ultrasound in the detection of liver metastases: a prospective multi-centre dose testing study using a perfluorobutane microbubble contrast agent (NC100100). Eur Radiol 2011; 21:1739.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/47\" class=\"nounderline abstract_t\">Quaia E, D'Onofrio M, Palumbo A, et al. Comparison of contrast-enhanced ultrasonography versus baseline ultrasound and contrast-enhanced computed tomography in metastatic disease of the liver: diagnostic performance and confidence. Eur Radiol 2006; 16:1599.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/48\" class=\"nounderline abstract_t\">Bernatik T, Schuler A, Kunze G, et al. Benefit of Contrast-Enhanced Ultrasound (CEUS) in the Follow-Up Care of Patients with Colon Cancer: A Prospective Multicenter Study. Ultraschall Med 2015; 36:590.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/49\" class=\"nounderline abstract_t\">Torzilli G. Advances in the surgical treatment of colorectal cancer liver metastases through ultrasound. Surg Today 2011; 41:1184.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/50\" class=\"nounderline abstract_t\">Donadon M, Torzilli G. Intraoperative ultrasound in patients with hepatocellular carcinoma: from daily practice to future trends. Liver Cancer 2013; 2:16.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/51\" class=\"nounderline abstract_t\">Leen E, Ceccotti P, Moug SJ, et al. Potential value of contrast-enhanced intraoperative ultrasonography during partial hepatectomy for metastases: an essential investigation before resection? Ann Surg 2006; 243:236.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/52\" class=\"nounderline abstract_t\">Ignee A, Baum U, Schuessler G, Dietrich CF. Contrast-enhanced ultrasound-guided percutaneous cholangiography and cholangiodrainage (CEUS-PTCD). Endoscopy 2009; 41:725.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/53\" class=\"nounderline abstract_t\">Seitz K, Bernatik T, Strobel D, et al. Contrast-enhanced ultrasound (CEUS) for the characterization of focal liver lesions in clinical practice (DEGUM Multicenter Trial): CEUS vs. MRI--a prospective comparison in 269 patients. Ultraschall Med 2010; 31:492.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/54\" class=\"nounderline abstract_t\">Konopke R, Kersting S, Bergert H, et al. Contrast-enhanced ultrasonography to detect liver metastases : a prospective trial to compare transcutaneous unenhanced and contrast-enhanced ultrasonography in patients undergoing laparotomy. Int J Colorectal Dis 2007; 22:201.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/55\" class=\"nounderline abstract_t\">Trillaud H, Bruel JM, Valette PJ, et al. Characterization of focal liver lesions with SonoVue-enhanced sonography: international multicenter-study in comparison to CT and MRI. World J Gastroenterol 2009; 15:3748.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/56\" class=\"nounderline abstract_t\">Dietrich CF, Maddalena ME, Cui XW, et al. Liver tumor characterization--review of the literature. Ultraschall Med 2012; 33 Suppl 1:S3.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/57\" class=\"nounderline abstract_t\">Strobel D, Bernatik T, Blank W, et al. Diagnostic accuracy of CEUS in the differential diagnosis of small (&le;&#8202;20 &#8202;mm) and subcentimetric (&le;&#8202;10&#8202; mm) focal liver lesions in comparison with histology. Results of the DEGUM multicenter trial. Ultraschall Med 2011; 32:593.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/58\" class=\"nounderline abstract_t\">Guang Y, Xie L, Ding H, et al. Diagnosis value of focal liver lesions with SonoVue&reg;-enhanced ultrasound compared with contrast-enhanced computed tomography and contrast-enhanced MRI: a meta-analysis. J Cancer Res Clin Oncol 2011; 137:1595.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/59\" class=\"nounderline abstract_t\">Westwood M, Joore M, Grutters J, et al. Contrast-enhanced ultrasound using SonoVue&reg; (sulphur hexafluoride microbubbles) compared with contrast-enhanced computed tomography and contrast-enhanced magnetic resonance imaging for the characterisation of focal liver lesions and detection of liver metastases: a systematic review and cost-effectiveness analysis. Health Technol Assess 2013; 17:1.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/60\" class=\"nounderline abstract_t\">Tranquart F, Correas JM, Ladam Marcus V, et al. [Real-time contrast-enhanced ultrasound in the evaluation of focal liver lesions: diagnostic efficacy and economical issues from a French multicentric study]. J Radiol 2009; 90:109.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/61\" class=\"nounderline abstract_t\">Albrecht T, Blomley MJ, Burns PN, et al. Improved detection of hepatic metastases with pulse-inversion US during the liver-specific phase of SHU 508A: multicenter study. Radiology 2003; 227:361.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/62\" class=\"nounderline abstract_t\">Catala V, Nicolau C, Vilana R, et al. Characterization of focal liver lesions: comparative study of contrast-enhanced ultrasound versus spiral computed tomography. Eur Radiol 2007; 17:1066.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/63\" class=\"nounderline abstract_t\">Harvey CJ, Blomley MJ, Eckersley RJ, et al. Hepatic malignancies: improved detection with pulse-inversion US in late phase of enhancement with SH U 508A-early experience. Radiology 2000; 216:903.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/64\" class=\"nounderline abstract_t\">Wilson SR, Kim TK, Jang HJ, Burns PN. Enhancement patterns of focal liver masses: discordance between contrast-enhanced sonography and contrast-enhanced CT and MRI. AJR Am J Roentgenol 2007; 189:W7.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/65\" class=\"nounderline abstract_t\">Kono Y, Steinbach GC, Peterson T, et al. Mechanism of parenchymal enhancement of the liver with a microbubble-based US contrast medium: an intravital microscopy study in rats. Radiology 2002; 224:253.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/66\" class=\"nounderline abstract_t\">Dietrich CF, Cui XW, Boozari B, et al. Contrast-enhanced ultrasound (CEUS) in the diagnostic algorithm of hepatocellular and cholangiocellular carcinoma, comments on the AASLD guidelines. Ultraschall Med 2012; 33 Suppl 1:S57.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/67\" class=\"nounderline abstract_t\">Barreiros AP, Piscaglia F, Dietrich CF. Contrast enhanced ultrasound for the diagnosis of hepatocellular carcinoma (HCC): comments on AASLD guidelines. J Hepatol 2012; 57:930.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/68\" class=\"nounderline abstract_t\">Dietrich CF, Mertens JC, Braden B, et al. Contrast-enhanced ultrasound of histologically proven liver hemangiomas. Hepatology 2007; 45:1139.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/69\" class=\"nounderline abstract_t\">Jeong MG, Yu JS, Kim KW. Hepatic cavernous hemangioma: temporal peritumoral enhancement during multiphase dynamic MR imaging. Radiology 2000; 216:692.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/70\" class=\"nounderline abstract_t\">Piscaglia F, Venturi A, Mancini M, et al. Diagnostic features of real-time contrast-enhanced ultrasound in focal nodular hyperplasia of the liver. Ultraschall Med 2010; 31:276.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/71\" class=\"nounderline abstract_t\">Dietrich CF, Schuessler G, Trojan J, et al. Differentiation of focal nodular hyperplasia and hepatocellular adenoma by contrast-enhanced ultrasound. Br J Radiol 2005; 78:704.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/72\" class=\"nounderline abstract_t\">Dietrich CF, Jenssen C. [Focal liver lesion, incidental finding]. Dtsch Med Wochenschr 2012; 137:2099.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/73\" class=\"nounderline abstract_t\">Kim TK, Jang HJ, Burns PN, et al. Focal nodular hyperplasia and hepatic adenoma: differentiation with low-mechanical-index contrast-enhanced sonography. AJR Am J Roentgenol 2008; 190:58.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/74\" class=\"nounderline abstract_t\">Ignee A, Piscaglia F, Ott M, et al. A benign tumour of the liver mimicking malignant liver disease--cholangiocellular adenoma. Scand J Gastroenterol 2009; 44:633.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/75\" class=\"nounderline abstract_t\">Dietrich CF, Ignee A, Greis C, et al. Artifacts and pitfalls in contrast-enhanced ultrasound of the liver. Ultraschall Med 2014; 35:108.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/76\" class=\"nounderline abstract_t\">Hirche TO, Ignee A, Hirche H, et al. Evaluation of hepatic steatosis by ultrasound in patients with chronic hepatitis C virus infection. Liver Int 2007; 27:748.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/77\" class=\"nounderline abstract_t\">Dietrich CF. Letter to the editor: Kratzer W et al. Prevalence and risk factors of focal sparing in hepatic steatosis. Ultraschall in Med 2010; 31: 37 - 42. Ultraschall Med 2010; 31:417.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/78\" class=\"nounderline abstract_t\">Janica J, Ustymowicz A, Lukasiewicz A, et al. Comparison of contrast-enhanced ultrasonography with grey-scale ultrasonography and contrast-enhanced computed tomography in diagnosing focal fatty liver infiltrations and focal fatty sparing. Adv Med Sci 2013; 58:408.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/79\" class=\"nounderline abstract_t\">Kim SH, Lee JM, Lee JY, et al. Value of contrast-enhanced sonography for the characterization of focal hepatic lesions in patients with diffuse liver disease: receiver operating characteristic analysis. AJR Am J Roentgenol 2005; 184:1077.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/80\" class=\"nounderline abstract_t\">Catalano O, Sandomenico F, Nunziata A, et al. Transient hepatic echogenicity difference on contrast-enhanced ultrasonography: sonographic sign and pitfall. J Ultrasound Med 2007; 26:337.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/81\" class=\"nounderline abstract_t\">Catalano O, Sandomenico F, Raso MM, Siani A. Low mechanical index contrast-enhanced sonographic findings of pyogenic hepatic abscesses. AJR Am J Roentgenol 2004; 182:447.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/82\" class=\"nounderline abstract_t\">Liu GJ, Lu MD, Xie XY, et al. Real-time contrast-enhanced ultrasound imaging of infected focal liver lesions. J Ultrasound Med 2008; 27:657.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/83\" class=\"nounderline abstract_t\">Thorelius L. Contrast-enhanced ultrasound in trauma. Eur Radiol 2004; 14 Suppl 8:P43.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/84\" class=\"nounderline abstract_t\">Thorelius L. Contrast-enhanced ultrasound: beyond the liver. Eur Radiol 2003; 13 Suppl 3:N91.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/85\" class=\"nounderline abstract_t\">Nilsson A, Lor&eacute;n I, Nirhov N, et al. Power Doppler ultrasonography: alternative to computed tomography in abdominal trauma patients. J Ultrasound Med 1999; 18:669.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/86\" class=\"nounderline abstract_t\">Cagini L, Gravante S, Malaspina CM, et al. Contrast enhanced ultrasound (CEUS) in blunt abdominal trauma. Crit Ultrasound J 2013; 5 Suppl 1:S9.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/87\" class=\"nounderline abstract_t\">Badea R, Seicean A, Procopet B, et al. Pseudoaneurysm of splenic artery ruptured in pancreatic pseudocyst and complicated by wirsungorrhagia: the role of the ultrasound techniques and contrast substances. Ultraschall Med 2011; 32:205.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/88\" class=\"nounderline abstract_t\">Stryckers M, Voet D, Vogelaers D, et al. Contrast-enhanced ultrasonography in hepatosplenic sarcoidosis. Acta Clin Belg 2011; 66:429.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/89\" class=\"nounderline abstract_t\">Lantinga MA, Gevers TJ, Drenth JP. Evaluation of hepatic cystic lesions. World J Gastroenterol 2013; 19:3543.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/90\" class=\"nounderline abstract_t\">Dong Y, Wang WP, Mao F, et al. Contrast enhanced ultrasound features of hepatic cystadenoma and hepatic cystadenocarcinoma. Scand J Gastroenterol 2017; 52:365.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/91\" class=\"nounderline abstract_t\">Schuessler G, Fellbaum C, Fauth F, et al. [The infammatory pseudotumour -- an unusual liver tumour]. Ultraschall Med 2006; 27:273.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/92\" class=\"nounderline abstract_t\">Weiss D, Marti G, Mouton W, et al. [Infection with fasciola hepatica - a case series]. Ultraschall Med 2010; 31:175.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/93\" class=\"nounderline abstract_t\">Wang ZL, Tang J, Weskott HP, et al. Undetermined focal liver lesions on gray-scale ultrasound in patients with fatty liver: characterization with contrast-enhanced ultrasound. J Gastroenterol Hepatol 2008; 23:1511.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/94\" class=\"nounderline abstract_t\">Barreiros AP, Braden B, Schieferstein-Knauer C, et al. Characteristics of intestinal tuberculosis in ultrasonographic techniques. Scand J Gastroenterol 2008; 43:1224.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/95\" class=\"nounderline abstract_t\">Xu HX, Xie XY, Lu MD, et al. Unusual benign focal liver lesions: findings on real-time contrast-enhanced sonography. J Ultrasound Med 2008; 27:243.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/96\" class=\"nounderline abstract_t\">Tana C, Silingardi M, Dietrich CF. New trends in ultrasound of hepatosplenic sarcoidosis. Z Gastroenterol 2015; 53:283.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/97\" class=\"nounderline abstract_t\">Tana C, Dietrich CF, Schiavone C. Hepatosplenic sarcoidosis: contrast-enhanced ultrasound findings and implications for clinical practice. Biomed Res Int 2014; 2014:926203.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/98\" class=\"nounderline abstract_t\">Kim SH, Lee JM, Kim WH, et al. Focal peliosis hepatis as a mimicker of hepatic tumors: radiological-pathological correlation. J Comput Assist Tomogr 2007; 31:79.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/99\" class=\"nounderline abstract_t\">Leinung S, G&uuml;tz U, St&ouml;lzel U, et al. [Peliosis hepatis: problems of differential diagnosis]. Rontgenpraxis 2000; 52:295.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/100\" class=\"nounderline abstract_t\">Okuda K, Omata M, Itoh Y, et al. Peliosis hepatis as a late and fatal complication of thorotrast liver disease. Report of five cases. Liver 1981; 1:110.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/101\" class=\"nounderline abstract_t\">Wang Z, Xu HX, Xie XY, et al. Imaging features of hepatic angiomyolipomas on real-time contrast-enhanced ultrasound. Br J Radiol 2010; 83:411.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/102\" class=\"nounderline abstract_t\">Rickes S, Wermke T, Ocran K, et al. [Contrast behaviour of a angiomyolipoma of the liver at echo-enhanced power-Doppler sonography]. Ultraschall Med 2002; 23:338.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/103\" class=\"nounderline abstract_t\">Dong Y, Wang WP, Cantisani V, et al. Contrast-enhanced ultrasound of histologically proven hepatic epithelioid hemangioendothelioma. World J Gastroenterol 2016; 22:4741.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/104\" class=\"nounderline abstract_t\">Trojan J, Hammerstingl R, Engels K, et al. Contrast-enhanced ultrasound in the diagnosis of malignant mesenchymal liver tumors. J Clin Ultrasound 2010; 38:227.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/105\" class=\"nounderline abstract_t\">Badea R, Chiorean L, Matei D, et al. Accidentally ingested foreign body associated with liver actinomycosis: the diagnostic value of imaging. J Gastrointestin Liver Dis 2013; 22:209.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/106\" class=\"nounderline abstract_t\">Hohmann J, Loddenkemper C, Albrecht T. Assessment of a biliary hamartoma with contrast-enhanced sonography using two different contrast agents. Ultraschall Med 2009; 30:185.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/107\" class=\"nounderline abstract_t\">Faust D, Fellbaum C, Zeuzem S, Dietrich CF. Nodular regenerative hyperplasia of the liver: a rare differential diagnosis of cholestasis with response to ursodeoxycholic acid. Z Gastroenterol 2003; 41:255.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/108\" class=\"nounderline abstract_t\">Ehrhardt AR, Reuter S, Buck AK, et al. Assessment of disease activity in alveolar echinococcosis: a comparison of contrast enhanced ultrasound, three-phase helical CT and [(18)F] fluorodeoxyglucose positron emission tomography. Abdom Imaging 2007; 32:730.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/109\" class=\"nounderline abstract_t\">Braden B, Helm B, Fabian T, Dietrich CF. [Bacillary angiomatosis of the liver, a suspected ultrasound diagnosis?]. Z Gastroenterol 2000; 38:785.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/110\" class=\"nounderline abstract_t\">Braden B, Thalhammer A, Schwarz W, Dietrich CF. Bleeding complications from hepatic mucoidal aneurysmata: value of color duplex sonography after liver transplantation. Liver Transpl 2002; 8:636.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/111\" class=\"nounderline abstract_t\">Tana C, Dietrich CF, Badea R, et al. Contrast-enhanced ultrasound in portal venous system aneurysms: a multi-center study. World J Gastroenterol 2014; 20:18375.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/112\" class=\"nounderline abstract_t\">Dietrich CF, Sharma M, Gibson RN, et al. Fortuitously discovered liver lesions. World J Gastroenterol 2013; 19:3173.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/113\" class=\"nounderline abstract_t\">Bernatik T, Seitz K, Blank W, et al. Unclear focal liver lesions in contrast-enhanced ultrasonography--lessons to be learned from the DEGUM multicenter study for the characterization of liver tumors. Ultraschall Med 2010; 31:577.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/114\" class=\"nounderline abstract_t\">Omata M, Lesmana LA, Tateishi R, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010; 4:439.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/115\" class=\"nounderline abstract_t\">Kudo M, Izumi N, Kokudo N, et al. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 2011; 29:339.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/116\" class=\"nounderline abstract_t\">International Consensus Group for Hepatocellular NeoplasiaThe International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 2009; 49:658.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/117\" class=\"nounderline abstract_t\">Boozari B, Soudah B, Rifai K, et al. Grading of hypervascular hepatocellular carcinoma using late phase of contrast enhanced sonography - a prospective study. Dig Liver Dis 2011; 43:484.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/118\" class=\"nounderline abstract_t\">Liu GJ, Xu HX, Lu MD, et al. Correlation between enhancement pattern of hepatocellular carcinoma on real-time contrast-enhanced ultrasound and tumour cellular differentiation on histopathology. Br J Radiol 2007; 80:321.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/119\" class=\"nounderline abstract_t\">Nicolau C, Catal&aacute; V, Vilana R, et al. Evaluation of hepatocellular carcinoma using SonoVue, a second generation ultrasound contrast agent: correlation with cellular differentiation. Eur Radiol 2004; 14:1092.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/120\" class=\"nounderline abstract_t\">Jang HJ, Kim TK, Burns PN, Wilson SR. Enhancement patterns of hepatocellular carcinoma at contrast-enhanced US: comparison with histologic differentiation. Radiology 2007; 244:898.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/121\" class=\"nounderline abstract_t\">Bhayana D, Kim TK, Jang HJ, et al. Hypervascular liver masses on contrast-enhanced ultrasound: the importance of washout. AJR Am J Roentgenol 2010; 194:977.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/122\" class=\"nounderline abstract_t\">Kim TK, Lee KH, Khalili K, Jang HJ. Hepatocellular nodules in liver cirrhosis: contrast-enhanced ultrasound. Abdom Imaging 2011; 36:244.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/123\" class=\"nounderline abstract_t\">Schellhaas B, Wildner D, Pfeifer L, et al. LI-RADS-CEUS - Proposal for a Contrast-Enhanced Ultrasound Algorithm for the Diagnosis of Hepatocellular Carcinoma in High-Risk Populations. Ultraschall Med 2016; 37:627.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/124\" class=\"nounderline abstract_t\">Piscaglia F, Cucchetti A, Dietrich CF, Salvatore V. Towards new tools for refined management of patients with advanced hepatocellular carcinoma under systemic therapy: some enthusiasm with a word of caution. J Hepatol 2013; 59:924.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/125\" class=\"nounderline abstract_t\">M&ouml;rk H, Ignee A, Schuessler G, et al. Analysis of neuroendocrine tumour metastases in the liver using contrast enhanced ultrasonography. Scand J Gastroenterol 2007; 42:652.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/126\" class=\"nounderline abstract_t\">D&ouml;rffel Y, Wermke W. Neuroendocrine tumors: characterization with contrast-enhanced ultrasonography. Ultraschall Med 2008; 29:506.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/127\" class=\"nounderline abstract_t\">Rickes S, Ocran KW, Gerstenhauer G, et al. Evaluation of diagnostic criteria for liver metastases of adenocarcinomas and neuroendocrine tumours at conventional ultrasound, unenhanced power Doppler sonography and echo-enhanced ultrasound. Dig Dis 2004; 22:81.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/128\" class=\"nounderline abstract_t\">Piscaglia F, Bolondi L, Italian Society for Ultrasound in Medicine and Biology (SIUMB) Study Group on Ultrasound Contrast Agents. The safety of Sonovue in abdominal applications: retrospective analysis of 23188 investigations. Ultrasound Med Biol 2006; 32:1369.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/129\" class=\"nounderline abstract_t\">Bokor D, Chambers JB, Rees PJ, et al. Clinical safety of SonoVue, a new contrast agent for ultrasound imaging, in healthy volunteers and in patients with chronic obstructive pulmonary disease. Invest Radiol 2001; 36:104.</a></li><li class=\"breakAll\">https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/203684Orig1s000Lbl.pdf (Accessed on September 26, 2017).</li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/131\" class=\"nounderline abstract_t\">Sidhu PS, Cantisani V, Deganello A, et al. Role of Contrast-Enhanced Ultrasound (CEUS) in Paediatric Practice: An EFSUMB Position Statement. Ultraschall Med 2017; 38:33.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/132\" class=\"nounderline abstract_t\">Chiorean L, Cui XW, Tannapfel A, et al. Benign liver tumors in pediatric patients - Review with emphasis on imaging features. World J Gastroenterol 2015; 21:8541.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/133\" class=\"nounderline abstract_t\">Schreiber-Dietrich D, Dietrich CF. Contrast enhanced ultrasound (CEUS) and off-label use (in children). Ultraschall Med 2012; 33:295.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/134\" class=\"nounderline abstract_t\">Dietrich CF, Ignee A, Hocke M, et al. Pitfalls and artefacts using contrast enhanced ultrasound. Z Gastroenterol 2011; 49:350.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/135\" class=\"nounderline abstract_t\">Nguyen BN, Fl&eacute;jou JF, Terris B, et al. Focal nodular hyperplasia of the liver: a comprehensive pathologic study of 305 lesions and recognition of new histologic forms. Am J Surg Pathol 1999; 23:1441.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/136\" class=\"nounderline abstract_t\">Ignee A, Weiper D, Schuessler G, et al. Sonographic characterisation of hepatocellular carcinoma at time of diagnosis. Z Gastroenterol 2005; 43:289.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions/abstract/137\" class=\"nounderline abstract_t\">Cui XW, Ignee A, Hocke M, et al. Prolonged heterogeneous liver enhancement on contrast-enhanced ultrasound. Ultraschall Med 2014; 35:246.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 96352 Version 8.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H61243901\"><span>SUMMARY</span></a></li><li><a href=\"#H92235595\" id=\"outline-link-H92235595\">INTRODUCTION</a></li><li><a href=\"#H92235607\" id=\"outline-link-H92235607\">GENERAL PRINCIPLES</a><ul><li><a href=\"#H60347672\" id=\"outline-link-H60347672\">Standard CEUS</a></li><li><a href=\"#H60347586\" id=\"outline-link-H60347586\">Additional CEUS imaging techniques</a></li></ul></li><li><a href=\"#H60340511\" id=\"outline-link-H60340511\">ADVANTAGES OF CEUS</a></li><li><a href=\"#H60338228\" id=\"outline-link-H60338228\">INDICATIONS</a><ul><li><a href=\"#H60340095\" id=\"outline-link-H60340095\">Detection and characterization of liver lesions</a><ul><li><a href=\"#H61235368\" id=\"outline-link-H61235368\">- Focal liver lesions</a></li><li><a href=\"#H61235572\" id=\"outline-link-H61235572\">- Liver metastases</a></li></ul></li><li><a href=\"#H60340102\" id=\"outline-link-H60340102\">Treatment planning</a><ul><li><a href=\"#H61239833\" id=\"outline-link-H61239833\">- Transcutaneous CEUS</a></li><li><a href=\"#H61239827\" id=\"outline-link-H61239827\">- Intraoperative CEUS</a></li></ul></li><li><a href=\"#H60340127\" id=\"outline-link-H60340127\">Treatment monitoring</a></li><li><a href=\"#H60340208\" id=\"outline-link-H60340208\">Liver transplantation</a></li><li><a href=\"#H60340352\" id=\"outline-link-H60340352\">Other diagnostic and therapeutic uses</a></li></ul></li><li><a href=\"#H57749551\" id=\"outline-link-H57749551\">ACCURACY</a></li><li><a href=\"#H61240290\" id=\"outline-link-H61240290\">FINDINGS ASSOCIATED WITH SPECIFIC LESIONS</a><ul><li><a href=\"#H60343227\" id=\"outline-link-H60343227\">Benign lesions</a></li><li><a href=\"#H60341910\" id=\"outline-link-H60341910\">Malignant lesions</a><ul><li><a href=\"#H3724156885\" id=\"outline-link-H3724156885\">- CEUS Liver Imaging Reporting and Data System (LI-RADS)</a></li></ul></li></ul></li><li><a href=\"#H92235833\" id=\"outline-link-H92235833\">SAFETY</a></li><li><a href=\"#H61243670\" id=\"outline-link-H61243670\">LIMITATIONS</a></li><li><a href=\"#H61243901\" id=\"outline-link-H61243901\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"GAST/96352|DiagnosticImage\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"DIAGNOSTIC IMAGES\">DIAGNOSTIC IMAGES</a></div><ul><li><a href=\"image.htm?imageKey=GAST/96803\" class=\"graphic graphic_diagnosticimage\">- CEUS of HCC after RFA</a></li><li><a href=\"image.htm?imageKey=GAST/96791\" class=\"graphic graphic_diagnosticimage\">- CEUS of a malignant liver lesion</a></li><li><a href=\"image.htm?imageKey=GAST/96792\" class=\"graphic graphic_diagnosticimage\">- CEUS of hepatic hemangioma</a></li><li><a href=\"image.htm?imageKey=GAST/96795\" class=\"graphic graphic_diagnosticimage\">- CEUS of FNH</a></li><li><a href=\"image.htm?imageKey=GAST/96802\" class=\"graphic graphic_diagnosticimage\">- CEUS of HA</a></li></ul></li><li><div id=\"GAST/96352|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=GAST/96793\" class=\"graphic graphic_table\">- CEUS findings in hemangioma</a></li><li><a href=\"image.htm?imageKey=GAST/96796\" class=\"graphic graphic_table\">- CEUS findings in FNH and HA</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=assessment-of-tumor-response-in-patients-receiving-systemic-and-nonsurgical-locoregional-treatment-of-hepatocellular-cancer\" class=\"medical medical_review\">Assessment of tumor response in patients receiving systemic and nonsurgical locoregional treatment of hepatocellular cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=chronic-portal-vein-thrombosis-in-adults-clinical-manifestations-diagnosis-and-management\" class=\"medical medical_review\">Chronic portal vein thrombosis in adults: Clinical manifestations, diagnosis, and management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-and-diagnosis-of-primary-hepatocellular-carcinoma\" class=\"medical medical_review\">Clinical features and diagnosis of primary hepatocellular carcinoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=contrast-echocardiography-contrast-agents-safety-and-imaging-technique\" class=\"medical medical_review\">Contrast echocardiography: Contrast agents, safety, and imaging technique</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-and-management-of-cystic-lesions-of-the-liver\" class=\"medical medical_review\">Diagnosis and management of cystic lesions of the liver</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=solid-liver-lesions-differential-diagnosis-and-evaluation\" class=\"medical medical_review\">Solid liver lesions: Differential diagnosis and evaluation</a></li></ul></div></div>","javascript":null}